Studies have shown that active fund managers routinely underperform the S&P500 index*​

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS)

ABOS Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
249.30%

ABOS Stock Analysis

ABOS PE Ratio:

ABOS PEG Ratio: Not Available

ABOS Forward EPS Growth (12 month): 0.00%

ABOS PS Ratio:

ABOS PSG Ratio: Not Available

ABOS Forward Revenue Growth (12 month): 0.00%

ABOS Articles

No data was found